BRONCHODYLATATORS IN TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The presented literature review considers the historical aspects of the use of bronchodilators (β2-adrenoagonists and cholinoblockers) in the treatment of chronic obstructive pulmonary disease (COPD). Mechanisms of the action of β2-adrenoagonists and cholinoblockers of various generations, including long-acting drugs (LABAs and LACBs) are discussed; the possibilities of use of long-acting drugs have significantly expanded in recent years. According to GOLD experts’ opinion, fixed-dose combinations of LABAs/LACBs should be considered as first-line drugs for most patients with symptomatic COPD and for almost everyone who needs regular supportive therapy. Great expectations are related to the introduction of triple fixed-dose combinations (LABAs, LACBs and inhaled glucocorticoids) into the practice of COPD pharmacotherapy. Obviously, the accumulation data from real clinical practice in the near and medium term, supplemented by the results of a number of direct comparative studies, will make it easier for the doctor to choose the «right drug» for the «right patient» with COPD.

Full Text

Restricted Access

About the authors

A. I Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Email: aisyn@list.ru
MD, Prof., Head of the Department of Pulmonology

References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2011.
  2. Miravitllesa M., Soler-Cataluna J.J., Calle M., et al. Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD. Aten Primaria. 2012;44:425-37. Doi: 10.1016/j. aprim.2012.04.005.
  3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2018.
  4. Miravitlles M., Soler-Cataluna J.J., Calle M., et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017: pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53:324-35. doi: 10.1016/j.arbres.2017.03.018.
  5. Qaseem A., Wilt T.J., Weinberger S.E., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-91. doi: 10.7326/0003-4819155-3-201108020-00008.
  6. Broncopneumopatia cronica ostruttiva. Linee guida nazionaii di riferimento er la prevenzione e la terapia.
  7. Aisanov Z., Avdeev S., Arkhipov V., et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J COPD. 2018;13:183-87. doi: 10.2147/COPD.S153770.
  8. Johnson M., Rennard S. Alternative mechanisms for long-acting beta (2)-adrenergic agonists in COPD. Chest. 2001;120:258-70.
  9. Hanania N.A., Moore R.H. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy. 2004; 3:271-77.
  10. Bennett W.D., Almond M.A., Zeman K.L., et al. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharmacol Ther 2006;19:96-100.
  11. Profita M., Giorgi R.D., Sala A., et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005;60:1361-69.
  12. Chen K.K., Schmodt C.F. The action and clinical use of ephedriean alkaloid isolated from the Chinese drug, ma huang. JAMA. 1926;87:836-42.
  13. Cazzola M., Page C.P, Calzetta L., et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450-504.
  14. Bullowa J.G.M., Kaplan D.M. On the hyperdermatic use of adrenalin chloride in the treatment of asthmatic attacks. Med News 1903;83:787.
  15. Barger G., Dale H.H. Chemical structure and sympathomimetic action of amines. J Physiol. 1910;4:19.
  16. Leifer K.N., Wittig H.J. The beta-2 sympathomimetic aerosols in the treatment of asthma. Ann Allergy. 1975;35:69-80.
  17. Williams D.M., Rubin B.K. Clinical pharmacology of bronchodilator medications. Respir Care. 2018;63:641-54. Doi: 10.4187/ respcare.06051.
  18. Chronic obstructive pulmonary disease. A systemic inflammatory disease. Eds. H. Nakamura, K. Aoshiba. Springer Nature: Singapore, 2017.
  19. Rau J.L. Inhaled adrenergic bronchodilators: historical development and clinical application. Respir Care. 2000;45:854-63.
  20. Billington C.K., Penn R.B., Hall I.P ß2-Agonists. Handb Exp Pharmacol. 2017;237:23-40. doi: 10.1007/164_2016_64.
  21. Bateman E.D., Rennard S., Barnes P.J., et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009;22:533-42. doi: 10.1016/j.pupt.2009.06.002.
  22. Jackson M. «Divine stramonium»: the rise and fall of smoking for asthma. Med Hist. 2010; 54:171-94.
  23. Rau J.L. Design principles of liquid nebulization devices currently in use. Respir Care. 2002;47:1257-75.
  24. Alagha K., Palot A., Safalvi T., et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis. 2014;5:85-98. doi: 10.1177/2040622313518227.
  25. Komiya K., Kawano S., Suzaki I., et al. Tiotropium inhibits mucin production stimulated by neutrophil elastase but not by IL-13. Pulm Pharm Therap. 2018; 48:161-67. Doi: 10.1016/j. pupt.2017.11.008.
  26. Fryer A.D., Jacoby D.B. Muscarinic receptors and control of airway smooth muscle. Am J Respir Crit Care Med. 1998;158(5 Pt 3):154-60.
  27. Kruse A.C., Li J., Hu J., et al. Novel insights into M3 muscarinic acetylcholine receptor physiology and structure. J Mol Neurosci. 2014;53:316-23. doi: 10.1007/s12031-013-0127-0.
  28. Miravitlles M., Vogelmeier C., Roche N., et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625-37. doi: 10.1183/13993003.01170-2015.
  29. Cramer J.A., Bradley-Kennedy C., Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir. J 2007;14:25-29.
  30. Boyd G, Morice A.H., Piunsford J.C., et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997; 10:815-21.
  31. Stockley R.A., Chorpa N., Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12-month study. Thorax. 2006; 61:122-28.
  32. Jones P.W., Bosh T.K. Quality of life changes in COPD patients treated with salmeterol. Amer J Respir Crit Care Med. 1997;155:1283-89.
  33. Tashkin D.P., Celli B., Senn S., et al. A 4-yaer trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-54.
  34. Celli B., Decramer M., Kesten S., et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Amer J Resir Crit Care Med. 2009; 180:948-55. doi: 10.1164/rccm.200906-0876OC.
  35. Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane DatabaseSyst Rev. 2014;(7):CD009285. doi: 10.1002/14651858.CD009285.pub3.
  36. Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(9):CD009552. doi: 10.1002/14651858. CD009552.pub2.
  37. Cazzola M., Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257-67. Doi: 10.1016/j. pupt.2010.03.003.
  38. Miravitlles M., Baek S., Vithlani V., Lad R. Optimal bronchodilation for COPD patients: are all long-acting ß2-agonist/long-acting muscarinic antagonists the same? Tuberc Respir Dis. 2018; 81:198-215. doi: 10.4046/trd.2018.0040.
  39. Price D., 0strem A., Thomas M., Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J COPD. 2017;12:141-68. doi: 10.2147/COPD. S116719.
  40. Rodrigo G.J., Price D., Anzueto A., et al. LABA/ LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J COPD. 2017; 12:907-22. doi: 10.2147/COPD.S130482.
  41. Bafadhel M., Peterson S., De Blas M.A., et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117-26. doi: 10.1016/S2213-2600(18)30006-7.
  42. Gibson P.G. Variability of blood eosinophils as a biomarker in asthma and COPD. Respirology. 2018;23:12-13. doi: 10.1111/resp.13200.
  43. Feldman G.J., Sousa A.R., Lipson D.A., et al. Comparative efficacy of once-daily umeclidinium/ vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv ther. 2017;34:2518-33. doi: 10.1007/s12325- 017-0626-4.
  44. Navarrete B.A., et al. Umeclidinium/ Vilanterol versus Tiotropium/Olodaterol in maintenance-naïve patients with moderate symptomatic chronic obstructive pulmonary disease: a post-hoc analysis. Pulm Ther. 2018.
  45. Calzetta L., Rogliani P, Matera M.G., Cazzola M. A Systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149:1181-96. doi: 10.1016/j.chest.2016.02.646.
  46. Lipson D.A., Barnhart F, Brealey N., et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671-80. doi: 10.1056/NEJMoa1713901.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies